Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down

by Zacks Equity Research

Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.

Theravance Pipeline Strong, Dependence on Yupelri a Concern

by Zacks Equity Research

Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down

by Zacks Equity Research

Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.

Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

by Zacks Equity Research

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should Value Investors Buy Mylan (MYL) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Top Ranked Value Stocks to Buy for January 27th

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, January 27th

Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

Should Value Investors Consider Mylan N.V. (MYL) Stock?

by Zacks Equity Research

Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

Sanghamitra Saha headshot

S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF

by Sanghamitra Saha

The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.

Sweta Killa headshot

10 Top-Ranked S&P 500 Stocks Outperforming in 2020

by Sweta Killa

The rally has been broad based and there are winners across various corners of the space.

Is Mylan (MYL) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?

by Zacks Equity Research

As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

Pfizer (PFE) Sees a Difficult 2019: Can it Rebound in 2020?

by Zacks Equity Research

Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.

Pfizer's Braftovi sNDA Accepted by FDA for Priority Review

by Zacks Equity Research

FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.

Why Is Mylan (MYL) Up 10% Since Last Earnings Report?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

by Zacks Equity Research

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

Acorda (ACOR) Down More Than 80% Year to Date: Here's Why

by Zacks Equity Research

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.

    Sanghamitra Saha headshot

    Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks

    by Sanghamitra Saha

    Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.

    Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase

    by Zacks Equity Research

    Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.

    Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

    by Zacks Equity Research

    Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.

    Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

      Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

      by Zacks Equity Research

      Mylan's (MYL) earnings beat estimates but sales miss the same in the third quarter of 2019. The company updates guidance for 2019.

      Mylan (MYL) Q3 Earnings Surpass Estimates

      by Zacks Equity Research

      Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

      Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More

      by Zacks Equity Research

      Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.

      Should You Buy Mylan (MYL) Ahead of Earnings?

      by Zacks Equity Research

      Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.